Evidence map›Paper›PMID 35908408›Full record

ArticleCytokine2022

Is IFN expression by NK cells a hallmark of severe COVID-19?

Bárbara Guimarães Csordas, Pedro Henrique de Sousa Palmeira, Rephany Fonseca Peixoto, Fernando Cézar Queiroz Davis Dos Santos Comberlang, Isac Almeida de Medeiros, Fátimade Lourdes Assunção Araújo de Azevedo, Robson Cavalcante Veras, Daniele Idalino Janebro, Ian P G Amaral, José Maria Barbosa-Filho and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cytokine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Bárbara Guimarães CsordasPostgraduate Program in Natural and Synthetic Bioactive Products, Immunology Laboratory of Infectious Diseases, Federal University of Paraiba, João Pessoa, Paraíba 58051-900, Brazil.
Pedro Henrique de Sousa PalmeiraPostgraduate Program in Physiology Science, Immunology Laboratory of Infectious Diseases, Department of Cellular and Molecular Biology, Federal University of Paraiba, João Pessoa, Paraíba 58051-900, Brazil.
Rephany Fonseca PeixotoPostgraduate Program in Physiology Science, Immunology Laboratory of Infectious Diseases, Department of Cellular and Molecular Biology, Federal University of Paraiba, João Pessoa, Paraíba 58051-900, Brazil.
Fernando Cézar Queiroz Davis Dos Santos ComberlangBiotechnology Graduation Program, Immunology Laboratory of Infectious Diseases, Federal University of Paraiba, João Pessoa, Paraíba 58051-900, Brazil.
Isac Almeida de MedeirosResearch Institute for Drugs and Medicines, Federal University of Paraiba, João Pessoa, Paraíba 58051-900, Brazil.
Fátimade Lourdes Assunção Araújo de AzevedoResearch Institute for Drugs and Medicines, Federal University of Paraiba, João Pessoa, Paraíba 58051-900, Brazil.
Robson Cavalcante VerasResearch Institute for Drugs and Medicines, Federal University of Paraiba, João Pessoa, Paraíba 58051-900, Brazil.
Daniele Idalino JanebroResearch Institute for Drugs and Medicines, Federal University of Paraiba, João Pessoa, Paraíba 58051-900, Brazil.
Ian P G AmaralBiotechnology Graduation Program, Immunology Laboratory of Infectious Diseases, Federal University of Paraiba, João Pessoa, Paraíba 58051-900, Brazil.
José Maria Barbosa-FilhoPharmaceutical Sciences Department, Federal University of Paraiba, João Pessoa, Paraíba 58051-900, Brazil.
Tatjana Souza Lima KeesenImmunology Laboratory of Infectious Diseases, Department of Cellular and Molecular Biology, Federal University of Paraiba, João Pessoa, Paraíba 58051-900, Brazil. Electronic address: tat.keesen@cbiotec.ufpb.br.
Universidade Federal da Paraíba · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural Killer cells (NK) are crucial in host defense against viruses. There are many unanswered questions about the immune system in COVID-19, especially the mechanisms that contribute to the development of mild or severe forms of the disease. Although NK cells may have an essential role in the pathogenesis of COVID-19, the mechanisms involved in this process are not yet fully elucidated. Here, we demonstrate that CD3

Indexed as

Antineoplastic AgentsCOVID-19GranzymesHepatitis A Virus Cellular Receptor 2HumansInterferon-alphaKiller Cells, NaturalPerforinAntineoplastic AgentsGranzymesHepatitis A Virus Cellular Receptor 2Interferon-alphaPerforinCOVID-19Cytotoxic granulesInnate immunityInterferonsNatural killersSARS-CoV-2

Identifiers

PMID35908408
PMCPMC9304336
OpenAlexW4286449165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.